In a recent study of 69 men with advanced prostate cancer undergoing paired plasma cfDNA whole-blood germline control sample analysis, 10% had CHIP variants in genes used for US FDA-approved PARP inhibitors, most frequently in ATM (53). This evidence concerns the gene STUB1 and prostate carcinoma.